• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cancer treatment: FDA panel says benefits of Novocure’s brain tumor device outweigh the risk

Cancer treatment: FDA panel says benefits of Novocure’s brain tumor device outweigh the risk

March 18, 2011 By MassDevice staff

glioblastoma

A new treatment for a deadly form of brain cancer has received a favorable vote from an FDA panel, moving the device a step closer to the market.

The FDA’s neurological devices panel voted 7-to-3 with 2 abstains that there is reasonable assurance that the benefits of the NovoTTF-100A System (NovoTTF) made by NovoCure, outweigh its risks when, “administered as a monotherapy in place of standard medical therapy,” according to a prepared release from the company.

Read all of our coverage on NeoCure’s revolutionary treatment for brain tumors

The NovoTFF is a “non-invasive device, consisting of four sets of insulated electrodes attached to an electronic box,” according to the privately-held Israeli company.

A favorable vote from an FDA panel typically results in the granting of premarket approval or a PMA to allow the device to be sold in the United States. However, the agency can still rule against the device.

The Food and Drug Administration is considering the device as a treatment for glioblastoma “after surgical and radiation options have been exhausted.” Glioblastoma is the most common form of brain tumor and has a low survival rate.

“We are pleased with the outcome of the Advisory Committee’s vote on the safety and effectiveness of NovoTTF,” said Eilon Kirson, Novocure’s chief medical officer.

On March 16 an FDA reviewers document posted on the agency’s web site said that clinical trials of the devices failed to show a significant increase in the overall survivability rate when measured against chemotherapy, but did significantly improve quality of life when compared to aggressive forms of chemotherapy.

Filed Under: News Well, Oncology Tagged With: NovoCure

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy